Literature DB >> 6642762

The use of calcium with verapamil in the management of supraventricular tachyarrhythmias.

A T Weiss, B S Lewis, D A Halon, Y Hasin, M S Gotsman.   

Abstract

Verapamil, a calcium channel blocking drug, terminates supraventricular arrhythmias but may have a negative inotropic effect and produce peripheral vasodilatation and hypotension. We studied the efficacy of intravenous calcium gluconate in reversing or preventing the hypotensive effect of verapamil in 31 patients with atrial tachyarrhythmias. In 21 instances, verapamil was given first, and in 13 calcium was used as pretreatment before the administration of verapamil. Calcium gluconate, when given as pretreatment, prevented the fall in blood pressure induced by verapamil, and when given after verapamil restored blood pressure to control values. The administration of calcium did not alter the antiarrhythmic effect of verapamil.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6642762     DOI: 10.1016/0167-5273(83)90084-0

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

2.  Biphasic dose-response relationship observed with Bay k 8644 on atrioventricular nodal conduction inhibited by verapamil.

Authors:  J Lang; Q Timour; J P Lançon; J F Aupetit; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

Review 3.  Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

Authors:  H O Klein; E Kaplinsky
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 4.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 5.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

6.  Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma.

Authors:  Qingjie Min; Yan Wang; Qingnan Wu; Xianfeng Li; Huajing Teng; Jiawen Fan; Yiren Cao; Pingsheng Fan; Qimin Zhan
Journal:  JCI Insight       Date:  2021-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.